Anna M. Eiring, Ph.D. - Publications

2009 Integrated Biomedical Sciences Ohio State University, Columbus, Columbus, OH 
Biomedical Engineering

19 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Ali AM, Gómez-Biagi RF, Rosa DA, Lai PS, Heaton WL, Park JS, Eiring AM, Vellore NA, de Araujo ED, Ball DP, Shouksmith AE, Patel AB, Deininger MW, O'Hare T, Gunning PT. Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities. Chemmedchem. PMID 27028877 DOI: 10.1002/cmdc.201600021  0.32
2015 Pomicter AD, Eiring AM, Senina AV, Zabriskie MS, Marvin JE, Prchal JT, O'Hare T, Deininger MW. Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm. Experimental Hematology. 43: 537-45.e1-11. PMID 25912019 DOI: 10.1016/j.exphem.2015.03.006  0.32
2015 Khorashad JS, Eiring AM, Mason CC, Gantz KC, Bowler AD, Redwine HM, Yu F, Kraft IL, Pomicter AD, Reynolds KR, Iovino AJ, Zabriskie MS, Heaton WL, Tantravahi SK, Kauffman M, et al. shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance. Blood. 125: 1772-81. PMID 25573989 DOI: 10.1182/blood-2014-08-588855  0.32
2015 Eiring AM, Page BD, Kraft IL, Mason CC, Vellore NA, Resetca D, Zabriskie MS, Zhang TY, Khorashad JS, Engar AJ, Reynolds KR, Anderson DJ, Senina A, Pomicter AD, Arpin CC, et al. Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia. 29: 586-97. PMID 25134459 DOI: 10.1038/leu.2014.245  0.32
2014 Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour EJ, Kornblau SM, Lipton JH, Rea D, ... ... Eiring AM, et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 26: 428-42. PMID 25132497 DOI: 10.1016/j.ccr.2014.07.006  0.32
2013 Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, et al. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. The Journal of Clinical Investigation. 123: 4144-57. PMID 23999433 DOI: 10.1172/JCI68951  0.32
2013 Corbin AS, O'Hare T, Gu Z, Kraft IL, Eiring AM, Khorashad JS, Pomicter AD, Zhang TY, Eide CA, Manley PW, Cortes JE, Druker BJ, Deininger MW. KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors. Cancer Research. 73: 5775-86. PMID 23887971 DOI: 10.1158/0008-5472.CAN-13-1318  0.32
2013 Khorashad JS, Kelley TW, Szankasi P, Mason CC, Soverini S, Adrian LT, Eide CA, Zabriskie MS, Lange T, Estrada JC, Pomicter AD, Eiring AM, Kraft IL, Anderson DJ, Gu Z, et al. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood. 121: 489-98. PMID 23223358 DOI: 10.1182/blood-2012-05-431379  0.32
2013 Hickey CJ, Schwind S, Radomska HS, Dorrance AM, Santhanam R, Mishra A, Wu YZ, Alachkar H, Maharry K, Nicolet D, Mrózek K, Walker A, Eiring AM, Whitman SP, Becker H, et al. Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia. Blood. 121: 159-69. PMID 23100311 DOI: 10.1182/blood-2012-05-428573  0.32
2012 O'Hare T, Zabriskie MS, Eiring AM, Deininger MW. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nature Reviews. Cancer. 12: 513-26. PMID 22825216 DOI: 10.1038/nrc3317  0.32
2010 Liu S, Wu LC, Pang J, Santhanam R, Schwind S, Wu YZ, Hickey CJ, Yu J, Becker H, Maharry K, Radmacher MD, Li C, Whitman SP, Mishra A, Stauffer N, ... Eiring AM, et al. Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell. 17: 333-47. PMID 20385359 DOI: 10.1016/j.ccr.2010.03.008  0.32
2010 Eiring AM, Harb JG, Neviani P, Garton C, Oaks JJ, Spizzo R, Liu S, Schwind S, Santhanam R, Hickey CJ, Becker H, Chandler JC, Andino R, Cortes J, Hokland P, et al. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell. 140: 652-65. PMID 20211135 DOI: 10.1016/j.cell.2010.01.007  0.32
2008 Eiring AM, Neviani P, Santhanam R, Oaks JJ, Chang JS, Notari M, Willis W, Gambacorti-Passerini C, Volinia S, Marcucci G, Caligiuri MA, Leone GW, Perrotti D. Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis. Blood. 111: 816-28. PMID 17925491 DOI: 10.1182/blood-2007-05-090472  0.32
2007 Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Gambacorti-Passerini C, Druker BJ, Cortes J, Marcucci G, Chen CS, Verrills NM, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. The Journal of Clinical Investigation. 117: 2408-21. PMID 17717597 DOI: 10.1172/JCI31095  0.32
2007 Chang JS, Santhanam R, Trotta R, Neviani P, Eiring AM, Briercheck E, Ronchetti M, Roy DC, Calabretta B, Caligiuri MA, Perrotti D. High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation. Blood. 110: 994-1003. PMID 17475908 DOI: 10.1182/blood-2007-03-078303  0.32
2005 Lunsford KE, Koester MA, Eiring AM, Horne PH, Gao D, Bumgardner GL. Targeting LFA-1 and cd154 suppresses the in vivo activation and development of cytolytic (cd4-Independent) CD8+ T cells. Journal of Immunology (Baltimore, Md. : 1950). 175: 7855-66. PMID 16339521  0.32
2005 Horne PH, Lunsford KE, Eiring AM, Wang Y, Gao D, Bumgardner GL. CD4+ T-cell-dependent immune damage of liver parenchymal cells is mediated by alloantibody. Transplantation. 80: 514-21. PMID 16123727 DOI: 10.1097/  0.32
2004 Lunsford KE, Gao D, Eiring AM, Wang Y, Frankel WL, Bumgardner GL. Evidence for tissue-directed immune responses: analysis of CD4- and CD8-dependent alloimmunity. Transplantation. 78: 1125-33. PMID 15502708 DOI: 10.1097/01.TP.0000138098.19429.99  0.32
2004 Gao D, Lunsford KE, Eiring AM, Bumgardner GL. Critical role for CD8 T cells in allograft acceptance induced by DST and CD40/CD154 costimulatory blockade. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 4: 1061-70. PMID 15196062 DOI: 10.1111/j.1600-6143.2004.00490.x  0.32
Show low-probability matches.